The company will be the exclusive U.S. distributor of fungal disease medication Posaconazole delayed-release tablets.
Purdue Pharma is offering to settle more than 2,000 lawsuits related to the opioid crisis, NBC reports.
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
By failing to settle like Purdue Pharma, JNJ is taking a risky gamble that could open itself up to many more state court battles and penalties.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
I am not focused on today's price movement of the stock but the pattern from the end of 2017.
J&J said it would appeal the judge's decision. The judgment was less than Wall Street was expecting. The stock rose after hours.
Here's how to empower the next generation of women going into STEM.
Here's how a project--such as reinventing the lab coat--can empower the minds of tomorrow.
The biopharmaceutical company reports positive Phase 3 trial results for its cholesterol-lowering therapy inclisiran.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.